Spravato vs At-Home Ketamine: Cost, Convenience, and Effectiveness

When patients research ketamine-based treatments for depression, they often encounter two distinct options: Spravato (esketamine), an FDA-approved nasal spray administered in clinical settings, and at-home sublingual ketamine therapy prescribed by telehealth providers like Tovani Health. While both harness ketamine's unique antidepressant properties, they differ substantially in formulation, delivery, cost, convenience, and patient experience. Understanding these differences is essential for making the right treatment choice.

The Chemistry: Esketamine vs Racemic Ketamine

Ketamine exists in two mirror-image molecular forms called enantiomers: S-ketamine (esketamine) and R-ketamine. Standard pharmaceutical ketamine is "racemic," meaning it contains equal parts of both forms.

Spravato contains only esketamine, the S-enantiomer. Johnson & Johnson patented this specific form and obtained FDA approval in 2019 for treatment-resistant depression and, subsequently, major depressive disorder with suicidal ideation.

At-home ketamine therapy uses racemic ketamine -- the mixture of both enantiomers that has been available as a generic medication for decades. When administered sublingually (dissolved under the tongue), it is absorbed through the oral mucosa into the bloodstream.

Does this chemical difference matter clinically? This is an active area of research. Some studies suggest that the R-enantiomer may actually contribute meaningfully to ketamine's antidepressant effects through mechanisms that esketamine alone does not fully engage. The racemic mixture may offer broader neurobiological coverage. However, both forms work through the glutamate-based mechanisms that make ketamine therapy effective.

The REMS Program: Spravato's Regulatory Framework

One of the most significant practical differences between Spravato and at-home ketamine is the regulatory framework governing Spravato's administration.

Spravato is subject to a Risk Evaluation and Mitigation Strategy (REMS) program mandated by the FDA. This means:

• It must be administered in a certified healthcare facility. You cannot take Spravato at home.
• You must be monitored for at least two hours after each dose by healthcare staff.
• You cannot drive on the day of treatment. You need someone to take you home.
• Each treatment requires an in-person visit to the certified facility.
• The prescribing provider must be specially certified through the REMS program.

These requirements exist because Spravato was the first FDA-approved ketamine-based product, and the regulatory approach reflected caution about a novel treatment mechanism. They ensure a high level of clinical oversight but also create significant logistical demands on patients.

At-home ketamine therapy, by contrast, is prescribed off-label under the prescribing clinician's medical judgment. While it involves its own safety requirements -- including a support person, medical screening, and activity restrictions -- it does not require travel to a clinical facility for each session.

Cost Comparison: The Numbers That Matter

Cost is often the deciding factor for patients, and the difference between these two options is substantial.

Spravato costs:

• The wholesale acquisition cost is approximately $590 to $885 per session (depending on dose)
• The initial treatment phase involves twice-weekly sessions for four weeks (eight sessions)
• Followed by weekly sessions, then biweekly maintenance
• Facility fees for the two-hour monitoring period add $100 to $300 per session
• Annual treatment costs can reach $25,000 to $40,000 before insurance

Insurance coverage for Spravato exists but comes with significant hurdles. Most insurance plans require prior authorization demonstrating failure of at least two antidepressant trials. Step therapy requirements may mandate trying other medications first. Copays, even with insurance, can be substantial. And the process of obtaining and maintaining authorization is often frustrating and time-consuming.

At-home ketamine therapy costs:

• Consultation and evaluation fees vary by provider
• Medication costs are significantly lower because racemic ketamine is a generic medication
• No facility or monitoring fees
• Total costs for an initial treatment course are typically a fraction of comparable Spravato treatment

Most at-home ketamine therapy is not covered by insurance because the use is off-label. However, the total out-of-pocket cost is frequently less than what patients pay in Spravato copays and facility fees even with insurance coverage.

Convenience and Accessibility

For many patients, the practical logistics of treatment are just as important as clinical considerations.

Spravato requires:

• Travel to a certified treatment center for every session
• Two or more hours at the facility per session (administration plus monitoring)
• Someone to drive you home after each session
• Significant time away from work, family, or other responsibilities
• Access to a certified Spravato center, which may not be available in all areas

At-home ketamine therapy requires:

• An adult support person present during treatment
• A quiet, comfortable space in your home
• 24-hour activity restrictions after each session
• No travel to or from a facility

For patients in rural areas, those with demanding work schedules, caregivers who cannot easily leave home, or anyone for whom regular travel to a medical facility is burdensome, the convenience advantage of at-home treatment is significant. Treatment happens in your own space, on your own schedule, without the stress of navigating traffic, parking, and waiting rooms while in a psychologically vulnerable state.

Clinical Effectiveness

This is the question patients care about most: which one works better?

The honest answer is that direct head-to-head comparison data is limited. Spravato's FDA approval was based on clinical trials demonstrating efficacy compared to placebo. Racemic ketamine has a much longer history of clinical use and research, with multiple studies and meta-analyses supporting its effectiveness for treatment-resistant depression.

What the available evidence suggests:

• Both esketamine and racemic ketamine produce rapid antidepressant effects
• Response rates for racemic ketamine in clinical studies are generally comparable to or slightly higher than those seen in Spravato's pivotal trials
• The broader mechanism of racemic ketamine (engaging both enantiomers) may offer theoretical advantages
• Route of administration (nasal spray vs sublingual) affects absorption and bioavailability differently

In practice, both treatments are effective for many patients with treatment-resistant depression. The clinical differences between them are less significant than the practical differences in cost, convenience, and accessibility.

When Spravato May Be the Better Choice

Despite the cost and logistical challenges, Spravato has genuine advantages for some patients:

• Insurance coverage potential. If your insurance covers Spravato with reasonable copays, the total cost may be lower than out-of-pocket at-home treatment.
• Clinical supervision preference. Some patients feel safer having medical staff immediately present during treatment. This is a valid preference, particularly for patients with significant anxiety about the experience.
• FDA approval. For patients or referring providers who place high value on FDA-approved status, Spravato offers that reassurance.
• Co-occurring medical conditions. Patients with complex medical profiles may benefit from the clinical monitoring environment.

When At-Home Ketamine Therapy May Be Better

For many patients, at-home therapy offers a more practical and sustainable treatment path:

• Cost constraints. When total out-of-pocket costs are the primary consideration, at-home therapy is typically more affordable.
• Geographic access. Patients who do not live near a certified Spravato center can access treatment through telehealth.
• Schedule flexibility. Treatments can be scheduled around your life rather than around clinic hours.
• Comfort and privacy. Many patients have a better therapeutic experience in their own home, which can enhance treatment outcomes.
• Sustainability. The lower logistical burden of at-home therapy makes it easier to maintain a consistent treatment schedule over time.

Making Your Decision

Both Spravato and at-home ketamine therapy represent genuine advances over traditional antidepressants for patients who have not found adequate relief. The best choice depends on your individual circumstances: insurance coverage, geographic access, personal preferences, medical history, and financial situation.

If you are considering at-home ketamine therapy through Tovani Health, our evaluation process will help determine whether this approach is appropriate for your specific situation. We consider your full medical and psychiatric history, current medications, and treatment goals.

Check your eligibility today to start a confidential evaluation and learn whether at-home ketamine therapy could be the right path forward for you.